Elekta highlights ASTRO data showing 37.4% two-year survival in localized pancreatic cancer patients treated on Unity MR-Linac
Bitget2026/09/28 17:02- Elekta flagged clinical results already presented at ASTRO 2026 on its Unity MR-Linac in localized pancreatic cancer.
- The Memorial Sloan Kettering study tracked non-surgical patients, showing durable tumor control with encouraging longer-term survival.
- Findings support broader uptake of MR-guided adaptive radiotherapy, a key growth area for Elekta’s high-end radiotherapy franchise.
- Elekta is advancing Unity with Unity Pro to speed workflows, aiming to make daily adaptive treatments more practical across centers.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Is AI an engine or a killer? Morgan Stanley provides answers with data: productivity soars, but nearly 90% of the benefits are taken by 12 industries
Morgan Stanley stated that the productivity dividends from AI are concentrated in 12 highly exposed industries, with growth rates reaching twice the twenty-year average. For the first time, signs of job replacement have emerged.
Production Increase Falls Short, Layoffs First! Boeing (BA.US) Cuts 5% of Commercial Airplane Jobs, Delays 737 Monthly Production Target of 47 Aircraft to 2027
Stephanie Pope, head of Boeing's commercial airplanes division, informed employees in an internal memo on Monday that due to obstacles in increasing aircraft production, the division plans to cut 5% of its workforce.
Crypto prices
More
